This page shows the latest idelalisib news and features for those working in and with pharma, biotech and healthcare.
EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has now confirmed that Zydelig (idelalisib) could cause serious illness, including Pneumocystis jirovecii pneumonia.
market share with other new CLL drugs such as Johnson &Johnson's Imbruvica (ibrutinib) and Gilead Sciences' Zydelig (idelalisib).
Venclexta will compete in the market with other new therapies for CLL, including Johnson &Johnson's first-in-class BTK inhibitor Imbruvica (ibrutinib) and Gilead Sciences' PI3 kinase inhibitor Zydelig (idelalisib),
The European Medicines Agency (EMA) said its review of Zydelig (idelalisib) was prompted by infections seen in three trials testing the drug in combination with other cancer medicines.
seen a string of new products enter the market such as Johnson &Johnson's first-in-class BTK inhibitor Imbruvica (ibrutinib) and Gilead Sciences' Zydelig (idelalisib).
s Zydelig (idelalisib).
More from news
Approximately 4 fully matching, plus 22 partially matching documents found.